Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENT-99: Sintilimab in Resectable NSCLC
NCT05116462Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sintilimab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Event Free Survival in stage III NSCLC at 2 years and Event Free Survival in ITT population at 3 years. Started Mar 2024; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05116462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116462.